STAT+: The future of cancer immunotherapy: your questions, answered

Last week, I hosted an hourlong webinar on future directions for cancer immunotherapy. I focused my talk on three promising avenues of research: checkpoint inhibitors that target the protein called TIGIT; cell therapies utilizing NK, or natural killer, cells; and messenger RNA-based cancer vaccines.

The goal with all of these approaches is to increase the number of patients with cancer who can benefit from immunotherapy.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: The future of cancer immunotherapy: your questions, answered »